|
CRC-survival (%)
|
1 yr
|
95 % CI
|
3 yrs
|
95 % CI
|
5 yrs
|
95 % CI
|
p-value#
|
---|
Total
| |
88
|
87 - 89
|
75
|
73 - 76
|
69
|
68 - 71
| |
Age group
|
50-59 yrs
|
91
|
89 - 92
|
75
|
72 - 78
|
68
|
65 - 71
| |
|
60-69 yrs
|
90
|
88 - 91
|
76
|
74 - 79
|
70
|
67 - 72
|
0.016
|
|
70-79 yrs
|
85
|
84 - 87
|
71
|
69 - 72
|
66
|
64 - 68
| |
Sex
|
Female
|
88
|
86 - 89
|
74
|
72 - 76
|
69
|
66 - 71
|
0.156
|
|
Male
|
88
|
87 - 89
|
74
|
72 - 75
|
67
|
65 - 69
| |
Private Insurance
|
No
|
85
|
83 - 86
|
71
|
69 - 73
|
65
|
62 - 67
|
<0.001
|
|
Yes
|
91
|
89 - 92
|
76
|
75 - 79
|
70
|
68 - 72
| |
Residence
|
Inner urban
|
88
|
87 - 89
|
75
|
72 - 76
|
69
|
66 - 69
| |
|
Outer urban
|
87
|
84 - 90
|
76
|
71 - 80
|
71
|
66 - 75
|
0.219
|
|
Rural
|
86
|
83 - 89
|
74
|
69 - 76
|
68
|
64 - 71
| |
|
Remote
|
89
|
83 - 92
|
73
|
66 - 79
|
64
|
56 - 70
| |
|
Very remote
|
84
|
67 - 92
|
75
|
57 - 86
|
59
|
38 - 76
| |
SES (quintiles)
|
Least advantaged
|
86
|
84 - 88
|
70
|
69 - 75
|
64
|
61 - 67
| |
|
Mid-low
|
87
|
85 - 89
|
74
|
71 - 77
|
68
|
65 - 71
| |
|
Mid
|
87
|
85 - 89
|
74
|
72 - 78
|
69
|
66 - 72
|
0.010
|
|
Mid-high
|
89
|
87 - 91
|
74
|
72 - 78
|
67
|
64 - 70
| |
|
Most advantaged
|
91
|
89 - 93
|
78
|
75 - 81
|
71
|
68 - 74
| |
ACP Stage
|
A
|
98
|
97 - 99
|
97
|
95- 98
|
95
|
93 - 96
| |
|
B
|
97
|
95 - 97
|
89
|
87 - 90
|
84
|
82 - 86
| |
|
C
|
91
|
89 - 92
|
72
|
69 - 74
|
62
|
59 - 64
|
<0.001
|
|
D
|
54
|
50 - 58
|
18
|
15 - 21
|
9
|
7 - 12
| |
|
Unknown
|
72
|
66 - 77
|
58
|
51 - 63
|
56
|
49 - 62
| |
Grade
|
Low
|
93
|
87 - 97
|
87
|
79 - 92
|
85
|
77 - 90
| |
|
Intermediate
|
93
|
92 - 94
|
81
|
80 - 82
|
75
|
73 - 76
|
<0.001
|
|
High
|
77
|
74 - 79
|
55
|
52 - 58
|
49
|
46 - 53
| |
|
Unknown
|
66
|
61 - 71
|
47
|
41 - 52
|
43
|
37 - 48
| |
Site
|
Colon
|
87
|
86 - 88
|
73
|
72 - 74
|
68
|
66 - 69
| |
|
Rectum
|
90
|
88 - 91
|
76
|
73 - 78
|
68
|
66 - 70
|
0.747
|
Co-morbidity
|
None
|
90
|
89 - 91
|
77
|
75 - 78
|
70
|
69 - 72
| |
|
One (not severe)
|
87
|
85 - 89
|
73
|
70 - 76
|
68
|
64 - 71
|
<0.001
|
|
Multiple / severe
|
75
|
71 - 78
|
58
|
54 - 62
|
52
|
48 - 56
| |
Surgery†
|
No
|
46
|
41 - 51
|
24
|
20 - 28
|
19
|
16 - 24
|
<0.001
|
|
Yes
|
92
|
91 - 93
|
79
|
77 - 80
|
73
|
71 - 74
| |
Radiotherapy†
|
No
|
88
|
87 - 89
|
75
|
74 - 76
|
70
|
68 - 71
|
<0.001
|
|
Yes
|
87
|
84 - 89
|
67
|
63 - 71
|
57
|
53 - 61
| |
Chemotherapy†
|
No
|
88
|
87 - 89
|
81
|
79 - 82
|
77
|
75- 79
|
<0.001
|
|
Yes
|
88
|
86 - 89
|
62
|
59 - 64
|
52
|
50 - 55
| |
- #Kaplan-meier log rank test
- †Treatments received within 12 months of diagnosis
- Mean follow-up time to death or censoring of 40 months (sd = 24 months), median 36 months (inter-quartile range 21-59 months